Critically, the experimental findings that PRSS2 is required for efficient tumor growth were validated by the observation that PRSS2 expression correlates with aggressive clinical features such as angiogenesis, tumor cell proliferation, disease progression, and survival in prostate cancer patients. Here, PRSS2 is linked to prostate carcinoma.